ArticleThe journal of allergy and clinical immunology. In practice2026
Mental Health in Eosinophilic Gastrointestinal Disorders: A Work Group Report of the AAAAI Eosinophilic Gastrointestinal Disorders Committee.
Article in The journal of allergy and clinical immunology. In practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Psychiatric comorbidities, including anxiety and depression, are increased in individuals with eosinophilic gastrointestinal disorder (EGID) compared with the general population. However, there are no established guidelines for screening and evaluating mental health disorders, and screening practices are unclear. We e-mailed an anonymous Web-based survey to members of the American Academy of Allergy, Asthma & Immunology and the Consortium of Eosinophilic Gastrointestinal Disease Researchers to examine mental health screening practices among clinicians caring for patients with EGIDs in the United States. Literature examining the association between mental health disorders and EGID was reviewed, best practices for anxiety and depression screening were discussed, and recommendations for implementing successful screening programs were formulated. Most survey respondents (62%; n = 31 of 50) indicated screening for anxiety and depression was important; however, only 18.6% (n = 11 of 59) conducted screening as part of standard clinical care for these patients. The most cited barriers to screening included a lack of time, limited expertise, and inadequate screening resources. This report provides recommendations and resources to facilitate the implementation of anxiety and depression screening in patients with EGIDs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.